An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.

Abstract

Antibody-cytokine fusion proteins (immunocytokines) are gaining importance for cancer therapy, but those products are often limited by systemic toxicity related to the activity of the cytokine payload in circulation and in secondary lymphoid organs. Tumor necrosis factor (TNF) is used as a pro-inflammatory payload to trigger haemorrhagic necrosis and boost anti-cancer immunity at the tumor site. Here we describe a depotentiated version of TNF (carrying the single point mutation I97A), which displayed reduced binding affinity to its cognate receptor tumor necrosis factor receptor 1 (TNFR-1) and lower biocidal activity. The fusion of the TNF(I97A) mutant to the L19 antibody promoted restoration of anti-tumor activity upon accumulation on the cognate antigen, the alternatively spliced EDB domain of fibronectin. In vivo administration of high doses (375 μg/Kg) of the fusion protein showed a potent anti-tumor effect without apparent toxicity compared with the wild type protein. L19-TNFI97A holds promise for the targeted delivery of TNF activity to neoplastic lesions, helping spare normal tissues.

• Authors: Sheila Dakhel, Christian Lizak, Mattia Matasci, Jacqueline Mock, Alessandra Villa, Dario Neri, Samuele Cazzamalli
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 18 (Sep 16 2021) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 34576184 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Cytokines
• Fibronectins
• Receptors, Tumor Necrosis Factor
• Receptors, Tumor Necrosis Factor, Type I
• Tumor Necrosis Factor-alpha

Topics

• Animals
• Antibodies, Monoclonal (metabolism)
• Antibodies, Monoclonal, Humanized (genetics, metabolism)
• Cricetulus
• Cytokines (genetics, metabolism)
• Female
• Fibronectins (genetics, metabolism)
• Fluorescent Antibody Technique
• Immunotherapy
• Mice, Inbred BALB C
• Mutation
• Protein Structure, Secondary
• Receptors, Tumor Necrosis Factor (genetics, metabolism)
• Receptors, Tumor Necrosis Factor, Type I (genetics, metabolism)
• Tumor Necrosis Factor-alpha (genetics, metabolism)